# Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

> **NCT01253642** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 11 (actual)

## Conditions studied

- Hormone-Resistant Prostate Cancer
- Metastatic Prostatic Adenocarcinoma
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma

## Interventions

- **PROCEDURE:** Biopsy of Prostate
- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Phenelzine Sulfate

## Key facts

- **NCT ID:** NCT01253642
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07-12
- **Primary completion:** 2016-09-15
- **Final completion:** 2017-09-15
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** low enrollment
- **Last updated:** 2019-10-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253642, "Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01253642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*